16 September 2026 note archive · Item
Allogeneic CD7-CAR-T (RD13-02): review notes
These archived notes document the scope reviewed on 16 September, including source-access limits. They do not cover later changes or newly added records. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: new record; substantive review 16 September 2026.
- Scope and findings: Added named RD13-02 donor-derived CD7-CAR-T programme, with current registry dose escalation, safety stopping rules, target 9 and stage 2/3 eligibility.
- Primary sources checked: NCT07528105 — study record (registry).
- Limits: No posted outcomes. Stage 2 eligibility does not establish preventive benefit, and a donor-cell protocol is not an approved treatment. No local recruitment confirmation beyond registry.